- Introduction
- Vision, Mission & Objective
- Organisation Chart
- Services
- Services Schedule
- Client Charter
- Related Information
Introduction
Nuclear Medicine is a branch of specialized medical field that uses radioactive tracers/radiopharmaceuticals for diagnosis, staging of disease, therapy and monitoring the response of a disease process.
For diagnostic studies, the radioactive tracer/radiopharmaceutical is administered to the patient mainly by intravenous injection, however a radioactive tracer may also be administered by inhalation, oral ingestion or direct injection into an organ depending on the organ and the function to be studied. The uptake, turnover and/or excretion of the tracer substance is then studied with a gamma camera (SPECT), Positron Emission Tomography (PET) camera or radiation detector.
As for therapeutic purpose, radioactive material/radiopharmaceutical is administered to the patient that bind to cancer cells and destroy them.
Vision
Nuclear medicine department shall be a centre of excellence in the provision of comprehensive, safe, up-to-date and compassionate nuclear medicine services to the community.
Mission
To provide quality and professional diagnostic and therapeutic nuclear medicine services through the safe use of radioactive substances.
Objectives
- To provide services in imaging, non-imaging and treatment using radioactive materials, method and facilities that are appropriate, accurate, safe and of the highest quality in patient care.
- To actively involved in the training of the healthcare personnel which will eventually translate into high standards of patient care.
- To carry out research and development pertaining to services provided.
Organisation Chart
Services
Provision of facilities for the assessment, diagnosis and treatment of diseases using unsealed radioactive
sources.
1.0 DIAGNOSTIC IMAGING – using SPECT modality
i. Bone Scintigraphy
Whole body +/- regional
Triple / 3 Phase
ii. Cardiac Scintigraphy
Cardiac Amyloidosis
Multi-gated blood pool (MUGA)
Myocardial perfusion – rest and stress
Viability
iii. Endocrine Scintigraphy
DMSA Pentavalent (V)
I-131 whole body – diagnostic and post-therapy
Meta Iodo Benzyl Guanidine (MIBG)
Parathyroid
Tc99m Thyroid
Thyroid uptake study
iv. Gastrointestinal Scintigraphy
Gastric emptying
Hepatobiliary Iminodiacetic Acid (HIDA)
Liver / spleen
Meckel’s Diverticulum
Red Blood Cell (RBC) tag
Salivary gland study
SeHCAT – malabsorption of bile
v. Infection Scintigraphy
Antigranulocyte antibody (Besilesomab)
White Blood Cells (WBC) tag
vi. Neurology Scintigraphy
Brain death
Brain perfusion
Ictal phase – epilepsy
TRODAT – Parkinsonism study
Ventriculo-peritoneal (VP) shunt
vii. Renal Scintigraphy
Diethylene Triamine Penta Acetic Acid (DTPA)
Dimercapto Succinic Acid (DMSA)
Direct radionuclide cystography
DTPA Captopril challenge
Mercapto Acetyl Triglycine (MAG3)
Testicular scan
viii. Respiratory Scintigraphy
Lung perfusion
Lung shunting
Lung ventilation / perfusion (Lung V/Q)
ix Others
Dacryoscintigraphy
Lymphoscintigraphy
Pleuro-peritoneal leaking study
Sentinel lymph node mapping – for breast cancer and melanoma
2.0 DIAGNOSTIC IMAGING – using PET modality
i. Infection/Inflammation
ii. Neurology
iii. Oncology
3.0 DIAGNOSTIC NON-IMAGING
i. Glomerular filtration rate (GFR) measurement
ii. Sentinel lymph node biopsy
iii. Radio-guided parathyroid surgery
4.0 THERAPY
i. Oncology
Cystic craniopharyngioma
I-131 for differentiated thyroid cancer.
I-131 MIBG for pheochromocytoma / neuroendocrine tumours & neuroblastoma.
Selective internal radiation therapy (SIRT) with Y-90 for patients having hepatobiliary carcinoma or liver metastasis.
ii. Non-oncology
I-131 for benign thyroid disease.
Radiosynoviorthesis.
Service Schedule
Monday | Tuesday | Wednesday | Thursday | Friday | |
DIAGNOSTIC STUDY (SCAN) | General scan, Rest MPI and MPI Counselling | ||||
Post-therapy WBS | Post-therapy WBS Diagnostic WBS | ||||
PROCEDURE | Stress MPI GFR | Stress MPI GFR | Stress MPI SLNM GFR | Stress MPI | SLNM |
CLINIC | Radioiodine and PET/CT Counselling | ||||
Admissions New cases | Admissions New cases Follow-up cases | Follow-up cases PET/CT | Follow-up cases PET/CT | Follow-up cases PET/CT Discharge |
Working Hour
Monday to Friday | 7.30 am to 5.30 pm |
Friday | Clinic is closed from 12.15 to 2.45pm |
Saturdays, Sundays & Public Holidays | ON CALL |
Client Charter
We in Nuclear Medicine Department, Hospital Kuala Lumpur will ensure:
i. every patient is given quality, patient oriented and timely service with emphasis on customer satisfaction. Priority is focused on customers who need immediate service.
ii. the dignity and confidentiality of patient information is maintained.
iii. patient is provided with professional, honest and sincere service by a team of skilled, committed and compassionate personnel.
iv. patient will be given clear explanation of agreed procedures and treatments including the risk and options available.
v. to complete patient’s report/study results within 5 working days for normal cases and 2 days for urgent cases.
iv. services given in the department are based on the followings:
a) waiting time prior to seeing the doctor is less than 90 minutes.
b) patients with benign thyroid disease will receive radioiodine therapy within 1 month.
Related Information
Nuclear Medicine Department is located at the First Floor of the Institute of Radiotherapy and Oncology Building, while our Radioiodine Ward is located on the Ground Floor of the same building.
Forms Related to Nuclear Medicine Department: